Clinical Trial Update: A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study evaluating intradermal administration of CryJ2-DNA-LAMP plasmid vaccine for allergic rhinitis, completed using the Bioje…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• CryJ2-DNA-LAMP plasmid vaccine (CryJ2-DNA-LAMP plasmid vaccine)

Snippet

Sponsor: Immunomic Therapeutics, Inc. | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED